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Summary
Objectives To assess the impact on health-related quality of life
(HRQoL) in adult cystic ﬁbrosis (CF) patients of chronic infection with the
Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa).
Design Cohort study.
Participants Adult CF patients attending a single CF centre.
Setting Outpatient clinic.
Main outcome measures HRQoL measures of adult CF patients
chronically infected with LES and Psa strains measured by CFQ-UK.
Results Patients infected by transmissible Psa strains had worse
physical functioning, respiratory symptoms, treatment burden, vitality,
role, health perception and emotion than those with unique Psa strains
(P < 0.01), and signiﬁcantly poorer physical functioning, respiratory
symptoms, treatment burden, body image, weight, role, and emotion than
those without any Psa infection (P < 0.05). Furthermore, in a matched
cohort of 39 patients, thosewith LES infection reported signiﬁcantly worse
physical functioning, treatment burden, respiratory symptoms and health
perception than those with unique Psa infection (P < 0.02).
Conclusion Chronic infection with transmissible Psa strains,
particularly LES, confers a worse quality of life in adult CF patients.
Coupled with the established poorer clinical outcome, this reinforces the
need to prevent the spread of such strains in CF community.
Introduction
Cystic ﬁbrosis (CF) is the commonest potentially
lethal inherited disease in the Western world.
Although it is incurable, survival in CF has
improved over the years and current epidemiolo-
gical data suggest that the average life expectancy
of an individual born with CF in the UK is now 38
years.
1 However, this is at the expense of a high
treatment burden, particularly in those chronically
infected with Pseudomonas aeruginosa (Psa) which
is known to confer increased morbidity and mor-
tality
2,3 and may therefore diminish their quality
of life (QoL).
The World Health Organization (WHO) has
deﬁned health as ‘a state of complete physical,
mental and social well being and not merely the
absence of disease or inﬁrmity’,
4 and therefore,
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RESEARCH
1in CF managing the patient’s psychological and
psycho-social wellbeing, which inﬂuence their
QoL, is as important as managing the physical
aspects of their disease.
Health-related quality of life (HRQoL) ques-
tionnaires can describe health outcomes in ways
that are meaningful to patients and families as
well as to healthcare professionals, and recently
a disease-speciﬁc HRQoL questionnaire (the
CFQ-US) has been developed for patients with
CF, and a UK version of this (the CFQ-UK) has
been validated for use without the loss of its psy-
chometric properties.
9
Although several studies have looked at QoL
in CF, few have investigated how an individual
patient’s disease state, particularly infection
with Psa, may impact on this. Recently, transmis-
sible Psa strains have been identiﬁed, the most
important of which is the Liverpool Epidemic
Strain (LES)
5 now widespread throughout UK
CF centres,
6 has also been reported in Canada
7
a n di sa s s o c i a t e dw i t haw o r s ec l i n i c a l
outcome.
8 We have a high incidence of LES Psa
infection in CF patients attending our adult
clinic: we were therefore interested to look at
the effect of Psa infection, and in particular that
due to LES, on the quality of their lives and
used the CFQ-UK for this purpose.
Methods
All 204 patients in a clinically stable state (i.e. no
exacerbation within the previous 4 weeks) attend-
ing a routine outpatient visit between August 2009
and March 2010 formed the potential study popu-
lation. Those with atypical CF or chronically
infected with Burkholderia cepacia complex were
excluded. Of the remaining 168 patients, 11 (5%)
refused to take part. Following informed
consent, 157 patients completed the CFQ-UK
(Teen/Adult revised, version 1)
9 prior to being
seen by a healthcare professional. Clinical details
(sputum microbiology, lung function, nutritional
state and diabetes mellitus) were retrieved from
the case records to aid subsequent data analysis.
This study was approved by the regional ethics
committee (Study Ref no 09/H1013/52: Oldham,
Tameside & Glossop & Salford & Trafford
Research Ethics Committees).
Psa infection state
All patients submit microbiological samples at
every clinic visit/inpatient stay: chronic infection
with Psa is deﬁned by at least three positive
sputum samples within a 6-month period.
10 Our
unit has pioneered Psa genotyping methodology
in CF, and we regularly genotype the Psa isolates
from our patients to aid cross-infection control
measures within the clinic: those without known
LES infection undergo genotyping using PCR
every 3 months to identify unique and other trans-
missible Psa strains,
11 while those infected with
LES undergo a genotypic check (using PCR and
primers PS21 & F9)
12 on a yearly basis. Using
this system, we are aware of the Psa genotypes
infecting our CF patients at all times.
Based on this, we divided the surveyed patients
into three groups: 93 with LES (all infected prior to
transfer from the paediatric sector), 44 with other
Psa strains (43 infected prior to transfer from the
paediatric sector), and the remaining 20 without
Psa infection or with persistently negative cultures
(six cases had undergone successful Psa eradica-
tion since transfer from the paediatric sector)
(Table 1).
Statistical analysis and patient
matching
The Kruskal-Wallis test was used to determine
differences between the three groups on all
12 CFQ-UK domains, and where signiﬁcant differ-
ences were noted individual comparisons
between groups were made using the Mann-
Whitney U test.
To overcome this, using all available patient
data we developed a multivariate logistic
regression model and generated a propensity
score for LES group membership
13,14 in order to
allow matching with patients infected with other
Psa strains. A full non-parsimonious model was
developed that included FEV1, BMI, age and
gender as independent variables and treatment
category as the dependent variable. The goal is
to balance recorded patient characteristics
between treatment groups by incorporating every-
thing recorded that may relate to either systematic
bias or simply bad luck.
The regression model had an appropriate
ﬁt (Hosmer–Lemeshow goodness-of-ﬁt χ
2 = 12.4
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Jack Kastelikand P =0.13) and acceptable discrimination (c
statistic, 0.78) indicating an acceptable ability to
differentiate between patients with or without
LES. We then used a macro (see http://www2.
sas.com/proceedings/sugi29/165-29.pdf) to
perform propensity-matching. Before matching,
the median propensity scores for patients with
and without LES were 0.70 and 0.66, respectively
(Wilcoxon signed-rank test P =0.036). After
matching, the median propensity scores for
patients with and without LES were 0.67 and
0.66, respectively (Wilcoxon signed-rank test P =
0.81).
Using this technique we were able to match 39
patients chronically infected with LES with 39
patients infected with other Psa strains. We did
not attempt to match LES patients with those
without Psa, since Psa infection per se is known
to confer a worse morbidity and mortality.
A P< 0.05 was considered to be signiﬁcant. All
statistical analysis was performed using SAS for
Windows Version 8.2.
Results
Thedemographicdetailsandclinicalcharacteristics
of the 157 patients who completed the CFQ–UK
questionnaire are given in Table 1. In our initial
unmatched cohort although there were no signiﬁ-
cant differences in age or FEV1 between groups,
patients chronically infected with LES had a
higher disease burden as evidenced by more with
CFRD (Cystic Fibrosis Related Diabetes Mellitus),
TIV AD (Totally Indwelling Venous Access Device)
implantation and the use of enteral feeding (all
P<0.005 compared to other groups). Patients
chronically infected with LES had a higher
disease burden compared to those with other Psa
strains or no Psa infection.
Using the Kruskall-Wallis test, comparison
across all three groups of patients produced signiﬁ-
cant differences in nine of the 12 HRQoL domains.
Individual comparisons between groups using the
Mann-Whitney U test across these nine domains
revealed that patients harbouring LES infection
had signiﬁcantly worse physical functioning, res-
piratory symptoms, treatment burden, vitality,
role, health perception and emotion than those
with unique Psa strains, and signiﬁcantly poorer
physical functioning, respiratory symptoms, treat-
ment burden, body image, weight, role and
emotion than those without any Psa infection.
However patients infected with unique Psa
strains only reported a worse perception of body
image than those with no Psa infection (Table 2).
Furthermore, in the matched cohort of 39
patients(Table3),thosewithLES infection reported
signiﬁcantly worse physical functioning, treatment
burden, respiratory symptoms and health percep-
tion than those with unique Psa infection
(Table 4), and ﬁve further domains (role, vitality,
body image, and emotional and social functioning)
approached statistical signiﬁcance.
Discussion
Although it is known that age, sex, FEV1, nutri-
tional state, the use of indwelling venous
devices, pulmonary exacerbations and the pres-
ence of diabetes can adversely affect the QoL in
CF patients;
15–17 little work has been done on
the effect of chronic infection in this group.
Table 1
Total study population demographics (n=157)
Psa strain
LES Other No Psa infection
Patients (n) 9 34 42 0
Women (%) 38 (51) 16 (38) 9 (48)
Median age, years (IQR) 26 (26–31) 22 (20–28) 21 (19–29)
Mean FEV1% (SD) 65 (23) 69 (23) 77.8 (26)
Mean BMI (SD) 21.7 (3.5) 22.6 (3.6) 25 (4.8)
Diabetes (%) 46 (49) 13 (29) 2 (10)
Enteral feed 5 1 0
TIVAD (%) 45 (48) 8 (18) 3 (15)
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3Studies looking at B cepacia infection have given
variable results. Duff
18 showed that segregation
from other patients caused feelings of isolation,
anger and of being a microbiological ‘leper’ but
did not use objective QoL assessment tools, and
although Gee
15 did not demonstrate any excess
effect of B cepacia infection compared to other
organisms, no details of disease severity were
recorded and the patient numbers were small.
As regards Psa infection, while Goldbeck
20
suggested that new infection had an independent
negative effect on QoL, the study was small and
did not achieve statistical signiﬁcance. Although
previous studies addressing the effect of chronic
Psa colonization have failed to show any adverse
effects, the study by Britto et al.
19 had poorly
matched groups, used a generic QoL question-
naire (sf-36) and only one-third of the participants
were adults, and the study by Havermans et al.
21
in 57 adult CF patients did not use patient match-
ing and no information regarding Psa strain types
was provided.
To our knowledge this is the ﬁrst study evaluat-
ing the health-related quality of life in a substan-
tial number of Psa-infected adult CF patients
including those chronically infected with the
most important such transmissible strain, LES.
For the ﬁrst time, we have shown that infection
with LES confers a worse quality of life in CF
than infection with other Psa strains and those
without any Psa, and this was conﬁrmed in
matched groups of patients. This is an important
T
a
b
l
e
2
D
i
f
f
e
r
e
n
c
e
i
n
H
R
Q
o
L

d
o
m
a
i
n
s
b
e
t
w
e
e
n
L
E
S
i
n
f
e
c
t
i
o
n
,
o
t
h
e
r
P
s
a
i
n
f
e
c
t
i
o
n
a
n
d
n
o
P
s
a
i
n
f
e
c
t
i
o
n
g
r
o
u
p
s
:
M
a
n
n
-
W
h
i
t
n
e
y
U
t
e
s
t
(
m
e
d
i
a
n
s
c
o
r
e
[
I
Q
R
]
)
(

h
i
g
h
e
r
s
c
o
r
e
s
i
n
d
i
c
a
t
e
b
e
t
t
e
r
o
u
t
c
o
m
e
s
)
–
U
n
m
a
t
c
h
e
d
g
r
o
u
p
s
M
i
c
r
o
b
i
o
l
o
g
y
O
t
h
e
r
P
s
a
N
o
P
s
a
P
L
E
S
N
o
P
s
a
P
L
E
S
O
t
h
e
r
P
s
a
P
P
h
y
s
i
c
a
l
f
u
n
c
t
i
o
n
7
9
(
5
8
–
9
6
)
7
5
(
5
6
–
9
4
)
N
S
5
8
(
3
3
–
8
7
)
7
5
(
5
6
–
9
4
)
0
.
0
3
5
8
(
3
3
–
8
7
)
7
5
(
5
6
–
9
4
)
0
.
0
0
0
3
R
o
l
e
8
3
(
5
8
–
1
0
0
)
8
3
(
6
2
–
1
0
0
)
N
S
7
5
(
5
0
–
9
2
)
8
3
(
6
2
–
1
0
0
)
0
.
0
4
7
5
(
5
0
–
9
2
)
8
3
(
5
8
–
1
0
0
)
0
.
0
1
V
i
t
a
l
i
t
y
5
8
(
5
0
–
7
5
)
5
8
(
3
3
–
9
1
)
N
S
5
0
(
3
3
–
6
6
)
5
8
(
3
3
–
9
1
)
N
S
5
0
(
3
3
–
6
6
)
5
8
(
5
0
–
7
5
)
0
.
0
0
8
E
m
o
t
i
o
n
8
0
(
6
6
–
9
3
)
8
3
(
6
3
–
9
3
)
N
S
7
3
(
5
3
–
8
6
)
8
3
(
6
3
–
9
3
)
0
.
0
5
7
3
(
5
3
–
8
6
)
8
0
(
6
6
–
9
3
)
0
.
0
2
B
o
d
y
i
m
a
g
e
7
8
(
5
5
–
1
0
0
)
1
0
0
(
1
0
0
–
1
0
0
)
0
.
0
0
8
6
7
(
4
4
–
1
0
0
)
1
0
0
(
1
0
0
–
1
0
0
)
0
.
0
0
0
9
6
7
(
4
4
–
1
0
0
)
7
7
(
5
5
–
1
0
0
)
N
S
R
e
s
p
i
r
a
t
o
r
y
s
y
m
p
t
o
m
s
6
7
(
5
0
–
8
3
)
7
7
(
6
7
–
8
6
)
N
S
5
5
(
3
9
–
7
2
)
7
7
(
6
7
–
8
6
)
0
.
0
0
0
2
5
5
(
3
9
–
7
2
)
6
7
(
5
0
–
8
3
)
0
.
0
0
2
T
r
e
a
t
m
e
n
t
b
u
r
d
e
n
6
7
(
5
5
–
7
6
)
7
2
(
3
3
–
8
3
)
N
S
5
5
(
4
4
–
6
7
)
7
2
(
3
3
–
8
3
)
0
.
0
1
5
5
(
4
4
–
6
7
)
6
7
(
5
5
–
7
6
)
0
.
0
1
H
e
a
l
t
h
p
e
r
c
e
p
t
i
o
n
6
7
(
5
5
–
7
8
)
6
7
(
0
–
8
9
)
N
S
5
5
(
3
3
–
6
7
)
6
7
(
0
–
8
9
)
N
S
5
5
(
3
3
–
6
7
)
6
6
(
5
5
–
7
8
)
0
.
0
1
W
e
i
g
h
t
1
0
0
(
6
7
–
1
0
0
)
1
0
0
(
1
0
0
–
1
0
0
)
N
S
1
0
0
(
3
3
–
1
0
0
)
1
0
0
(
1
0
0
–
1
0
0
)
0
.
0
1
1
0
0
(
3
3
–
1
0
0
)
1
0
0
(
1
0
0
–
1
0
0
)
N
S
Table 3
Univariate demographics in LES infected and
other Psa infected – matched group Continuous
variables are shown as mean (standard devi-
ation) Categorical variables are shown as a
number (percentage)
Other Psa
infection
(n = 39)
LES
infection
(n = 39)
P
value
Women (%) 14 (37) 11 (28) 0.36
Age (years) 28 (8) 28 (9) 0.66
BMI (SD) 22.6 (3.6) 22.3 (3.1) 0.80
FEV1(SD) 71 (22) 69 (21) 0.77
Diabetes (%) 11 (28) 18 (46) 0.15
Enteral feeding 1 2 1.00
TIVAD (%) 12 (31) 21 (53) 0.66
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4ﬁnding that needs to be heeded by the CF health-
care community.
LES ﬁrst came to light in 1996 at our local pae-
diatric CF centre,
5 and is now widespread
throughout UK CF clinics.
6 It has also been
reported at a CF centre in Canada.
7 It is highly
transmissible – it can super-infect patients
already possessing other Psa strains,
22 can
spread to non-CF relatives,
23 and also cross-infect
other species.
24 We have a large cohort of such
patients, mainly inherited from the paediatric
sector and have already shown that these patients
have a poorer prognosis
8 and increased treatment
burden
25 than other (matched) patients. It is there-
fore not surprising that these individuals also
have a poorer quality of life.
Furthermore, LES-infected patients not only
scored more poorly in those domains assessing
physical wellbeing (physical function, treatment
burden, weight, and respiratory symptoms) but
also in those assessing psychological functioning
(vitality, emotion, health perception and body
image). The impairment of physical domain QoL
indicators are expected as LES is known to cause
a more rapid decline in lung function, weight,
and increase the need for IV antibiotics, triggering
the need for extra therapy which in turn results in
a higher treatment burden. However, the poorer
scores in the psychological domain indicators
suggest that LES has a more profound effect on
these individuals than that expressed by physical
deterioration alone. This combination of poor per-
ceived physical parameters (poor physical func-
tion, treatment burden, weight, and respiratory
symptoms scores) and higher psychological
burden (poor vitality, emotion, health perception
and body image scores) in patients with LES may
result in an overall worse HRQoL compared to
those infected with other Psa strains or without
Psa infection.
However, the cohort of LES-infected patients in
our study were older and had poorer pulmonary
function and had a higher disease burden as evi-
denced by higher incidence of CFRD, those with
TIV AD’s and needing enteral feeds than the
remainder, suggesting that at least some of these
differences in quality of life could be due to this.
It was for this reason that we compared matched
groups, obtained using a validated statistical pro-
pensity scoring system. In this matched group of
patients infected with Psa strains, those with LES
still demonstrated a signiﬁcantly worse perception
of physical (physical function, treatment burden,
respiratory symptoms) and psychological (health
perception) wellbeing compared to patients with
other Psa strains. Furthermore, although other
aspects of psycho-social wellbeing (role, vitality,
emotional function, social function and body
image) failed to achieve statistical signiﬁcance,
there were strong trends, indicating that these
changes are a true reﬂection of the patients’ LES
infection status. It was for this reason that we
opted not to use alpha correction (e.g. Bonferroni)
for group matching since the differences between
the matched groups (without correction) were
close to the level of signiﬁcance: this is highly unli-
kely to be a chance occurrence.
In contrast, patients infected with other Psa
strains only had an altered body image compared
to patients without Psa infection, suggesting that
acquisition of sporadic Psa may not signiﬁcantly
impact on the psychological wellbeing of the
individual.
It has already been shown that depression and
anxiety are more common in CF
26 and can
adversely affect their QoL: anxious patients
report more respiratory symptoms, have a poorer
perception of their health and treatment burden,
and poorer social and emotional functioning,
Table 4
HRQoL outcomes in LES infected and Other Psa infected Matched
Groups: Mann-Whitney U test
QoL dimension Other Psa infection
(n = 39)
LES infection
(n = 39)
P
value
Physical function 84 (63–100) 72 (33–88) 0.02
Role 84 (67–100) 76 (50–92) 0.06
Vitality 59 (50–75) 51 (33–67) 0.06
Emotional
function
81 (67–93) 74 (53–93) 0.07
Social function 79 (61–83) 68 (50–83) 0.07
Body image 89 (56–100) 68 (44–100) 0.09
Eating 100 (89–100) 100 (78–100) 0.16
Treatment burden 68 (56–78) 57 (44–67) 0.02
Health perception 68 (56–89) 57 (33–78) 0.01
Weight 100 (67–100) 100 (33–100) 0.36
Respiratory
symptoms
73 (50–83) 62 (44–72) 0.006
Digestion 89 (67–100) 89 (67–100) 0.70
Higher scores indicate better outcomes
Variables quoted as median (interquartile range)
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5while those with depression show a poorer body
image, eating disturbances and emotional func-
tioning.
27 Although our study was not designed
to address the prevalence of anxiety and
depression among our patients, it may be that
these factors also contribute to the poorer QoL
outcomes in patients infected with epidemic
strains and this merits further study.
This large cross-sectional QoL study adds
further evidence to the poor outcomes associated
with chronic infection with transmissible Psa
strains in CF: those harbouring LES reported
worse scores across most HRQoL domains com-
pared to patients without such infection.
There are limitations to our study: we only
looked at one centre with a high prevalence of
one transmissible Psa strain (LES) and used a
cross-sectional design, and it may be that the
results cannot be generalized to other transmissi-
ble Psa strains or the CF population at large.
Nevertheless, LES is the most prevalent transmis-
sible strain in the UK and has already spread to
units elsewhere, so our ﬁndings will be of rel-
evance to many CF clinics. Also, this is the
largest study of the measurement of QoL in
adult CF patients, using a new validated tool,
which is increasingly being employed in the holis-
tic assessment of this chronic disease group.
Although longitudinal studies with repeated
QoL measurements before and after chronic infec-
tion with such transmissible epidemic strains are
needed to address their true effect on QoL in CF
patients, our study does highlight the physical as
well as psychosocial limitations faced by patients
infected with such epidemic strains.
Prevention of cross-infection with transmissible
strains is essential to ensure better physical and
psychological outcomes for these patients, and
such strategies shouldbeadopted byall CF centres.
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